Blog

Home  /  News   /  The Joint Assessment on “Vorapaxar (ZONTIVITY™) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)” is now available

The Joint Assessment on “Vorapaxar (ZONTIVITY™) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)” is now available

The Joint Assessment on “Vorapaxar (ZONTIVITY™) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)” is now available

Find the Joint Assessment here.